ATE398459T1 - Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen - Google Patents

Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen

Info

Publication number
ATE398459T1
ATE398459T1 AT97924210T AT97924210T ATE398459T1 AT E398459 T1 ATE398459 T1 AT E398459T1 AT 97924210 T AT97924210 T AT 97924210T AT 97924210 T AT97924210 T AT 97924210T AT E398459 T1 ATE398459 T1 AT E398459T1
Authority
AT
Austria
Prior art keywords
naip
prevention
iap
treatment
neuronal diseases
Prior art date
Application number
AT97924210T
Other languages
English (en)
Inventor
Robert Korneluk
Alexander MACKENZIE
George Robertson
D Xu
S Krocker
Original Assignee
Univ Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ottawa filed Critical Univ Ottawa
Application granted granted Critical
Publication of ATE398459T1 publication Critical patent/ATE398459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97924210T 1996-04-26 1997-04-25 Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen ATE398459T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1735496P 1996-04-26 1996-04-26
US3059096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
ATE398459T1 true ATE398459T1 (de) 2008-07-15

Family

ID=26689763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97924210T ATE398459T1 (de) 1996-04-26 1997-04-25 Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen

Country Status (6)

Country Link
US (3) US6159948A (de)
EP (1) EP0840617B1 (de)
AT (1) ATE398459T1 (de)
CA (1) CA2222453C (de)
DE (1) DE69738776D1 (de)
WO (1) WO1997040847A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087173A (en) * 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US6511828B1 (en) 1996-05-31 2003-01-28 Arch Development Corporation Human and drosophila inhibitors of apoptosis proteins (IAPs)
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
DE69836982T2 (de) * 1997-08-14 2007-10-31 Institut Pasteur Hybride Tetanustoxinproteine die retrograd und transsynaptisch ins ZNS migrieren
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO1999062943A2 (en) * 1998-06-02 1999-12-09 Millenium Pharmaceuticals, Inc. Novel molecules of the aip-related protein family and uses thereof
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US20060212025A1 (en) 1998-11-30 2006-09-21 Light Bioscience, Llc Method and apparatus for acne treatment
US6283956B1 (en) 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US9192780B2 (en) * 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
JP2004531731A (ja) * 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
US6573300B2 (en) 2001-08-24 2003-06-03 China Medical College Hospital Hydroxyurea treatment for spinal muscular atrophy
US20060057109A1 (en) * 2002-03-25 2006-03-16 Waxman David J Method of using anti-apoptotic factors in gene expression
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
CN1784184A (zh) * 2003-04-10 2006-06-07 光生物科学有限责任公司 调节细胞增殖以及基因表达的光调节方法以及装置
CA2533129A1 (en) 2003-07-31 2005-02-10 Light Bioscience, Llc System and method for the photodynamic treatment of burns, wounds, and related skin disorders
EP1807157A2 (de) 2004-10-22 2007-07-18 Neurologix, Inc. Verwendung von apoptoseverhindernden verbindungen bei neurologischen degenerationserkrankungen
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1955190B1 (de) 2005-11-10 2018-08-29 In Silico Biosciences, Inc. Verfahren und vorrichtung zur computermodellierung des menschlichen gehirns zur vorhersage von medikamenteneffekten
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006814A1 (en) * 1992-09-14 1994-03-31 The General Hospital Corporation Ikaros: a t cell pathway regulatory gene
EP0770129B1 (de) * 1994-01-18 2005-11-23 The Scripps Research Institute Derivate von zinkfingerproteinen und methoden
JP3944654B2 (ja) * 1994-10-18 2007-07-11 ザ ユニバーシティー オブ オタワ 神経細胞アポトーシスの抑制タンパクとその遺伝子配列、並びに脊髄性筋萎縮症の原因となる当該遺伝子の突然変異
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)

Also Published As

Publication number Publication date
DE69738776D1 (de) 2008-07-31
WO1997040847A1 (en) 1997-11-06
EP0840617B1 (de) 2008-06-18
EP0840617A1 (de) 1998-05-13
US6709866B2 (en) 2004-03-23
US20010021699A1 (en) 2001-09-13
CA2222453C (en) 2009-06-30
CA2222453A1 (en) 1997-11-06
US6159948A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
DE69738776D1 (de) Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE60138019D1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
EP1463531A4 (de) Verfahren zur hemmung okularer vorgänge
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE69224069D1 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DE69426033D1 (de) Für die alpha-1e untereinheit des menschlichen kalziumkanals kodierende dna
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
BR9807883A (pt) Compostos de tetraidropirido
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
BR0314541A (pt) Tratamento de demência e doença de parkinson

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties